Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Adult Blepharitis Medication

  • Author: R Scott Lowery, MD; Chief Editor: John D Sheppard, Jr, MD, MMSc  more...
 
Updated: Dec 31, 2015
 

Medication Summary

Useful medications in the treatment of blepharitis may include topical antibiotics, topical corticosteroids, and oral antibiotics. Typical blepharitis may be treated with a hygiene regimen and topical antibiotic ointment. Use of combination corticosteroid and antibiotic ointment should not be long term but may prove useful in reduction of inflammation in difficult cases. Oral tetracycline class antibiotics may be required for refractory cases. Also, a combination antibiotic and steroid drop may be required for associated corneal disease.[6]

Ivermectin is a broad-spectrum antiparasitic drug used mainly to treat strongyloidiasis and onchocerciasis; although strong evidence upholds its off-label use against some arthropods. For patients with refractory blepharitis, ivermectin has been found to lessen the number of Demodex folliculorum found in the lashes.

In a noncomparative, interventional case series, researchers examined 24 eyes of 12 patients with refractory posterior blepharitis with the presence of D folliculorum in lash samples.[7] Patients were instructed to take 1 dose of oral ivermectin (200 ug/kg) and to repeat the treatment after 7 days. The researchers obtained tear meniscus height, Schirmer test results, noninvasive tear film break-up time, corneal fluorescein and rose bengal staining scores, and quantification of the absolute number of D folliculorum found in lashes from all patients 1 day before and 28 days after the 2-dose treatment.

A significant reduction was observed in the absolute number of D folliculorum found in the lashes after the treatment with oral ivermectin. Average values of Schirmer test results and tear film break-up time improved substantially after the treatment of oral ivermectin. The authors observed no significant improvement in average lacrimal meniscus height or value of corneal fluorescein and rose bengal staining after treatment with oral ivermectin.[7]  

Next

Topical antibiotic ointments

Class Summary

Useful in targeting offending pathogens, usually Staphylococcus aureus (and possibly other Staphylococcus, Propionibacterium, Demodex, and Pityrosporum species, which chronically infect the lashes); the mechanism of action seems to be reduction of staphylococcal lipase production more than actual bacterial elimination.

Erythromycin ophthalmic (E-Mycin)

 

Erythromycin ointment is applied to lid margins with a clean vector, such as a cotton swab or a clean fingertip, after crusting and debris have been removed with gentle cleansing or scrubbing.

Bacitracin ophthalmic (Bacitracin Ophthalmic Ointment)

 

Bacitracin ointment is also applied to lid margins with a clean vector, such as a cotton swab or a clean fingertip, after crusting and debris have been removed with gentle cleansing or scrubbing. 

Previous
Next

Topical antibiotic/corticosteroid suspension/ointment

Class Summary

Topical corticosteroids, combined with an antibiotic, may be useful in the short-term treatment of blepharitis to decrease inflammation and more quickly diminish symptoms. Long-term use is not recommended. An ointment may be used for blepharitis, while a drop may be needed if associated corneal disease develops.

Sulfacetamide sodium and prednisolone acetate (Blephamide)

 

Sulfacetamide is an antibiotic that, like erythromycin, has been shown to be effective against staphylococci. The combined corticosteroid is useful in decreasing inflammation and decreasing symptoms. Use of the 2 agents combined has been shown to increase patient compliance. Blephamide is available in an ophthalmic suspension and in an ointment, both containing the same concentrations of active ingredients (10% sulfacetamide/0.2% prednisolone).

Previous
Next

Oral antibiotics

Class Summary

Staphylococcal blepharitis usually responds more quickly to combined use of topical and oral antibiotics, although a trial of topical antibiotics alone usually is indicated before oral antibiotics should be considered. Tetracyclines are the DOC.

Tetracycline (Sumycin)

 

Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s). Metabolized by the liver and the kidneys. Usually not the DOC for most staphylococcal infections but has been shown to be effective in the treatment of refractory blepharitis, in which Staphylococcus aureus is the usual pathogen. Tetracyclines should not be taken with antacids or foods, but rather, they should be taken 1-2 h after meals.

Doxycycline (Bio-Tab, Doryx, Vibramycin, Doxy)

 

Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Previous
Next

Anthelmintic

Class Summary

For patients with refractory blepharitis, ivermectin has been used off-label to lessen the number of Demodex folliculorum found in the lashes. Ivermectin is a broad-spectrum antiparasitic drug.

Ivermectin (Stromectol)

 

Binds selectively with glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing cell death. Off-label use has been described for blepharitis associated with Demodex folliculorum.

Previous
Next

Dermatology, Herbals

Tea tree oil (Australian tea tree oil, Cymeme, Melaleuca alternifolia)

 

Tea tree oil provides a direct ant-parasitic effect upon D folliculorum. Tea tree oil, the essential oil derived from the native plant Melaleuca alternifolia, is characterized by 15 major components. Scientific studies have shown that 4-Terpineol, or Terpinen-4-ol (T4O), is the most important ingredient in tea tree oil. Tea tree oil is available commercially and from numerous natural-remedy companies. The active ingredient is available through BioTissue (Cliradex).

Previous
 
 
Contributor Information and Disclosures
Author

R Scott Lowery, MD Associate Professor of Ophthalmology, Department of Pediatric Ophthalmology and Strabismus, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

R Scott Lowery, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, Arkansas Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, International Society of Refractive Surgery, Cornea Society, Eye Bank Association of America

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

John D Sheppard, Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard, Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, American Uveitis Society

Disclosure: Nothing to disclose.

Additional Contributors

Fernando H Murillo-Lopez, MD Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May. 31 (5):472-8. [Medline].

  2. Pinckney J 2nd, Cole P, Vadapalli SP, Rosen T. Phthiriasis palpebrarum: a common culprit with uncommon presentation. Dermatol Online J. 2008 Apr 15. 14(4):7. [Medline].

  3. Divani S, Barpakis K, Kapsalas D. Chronic blepharitis caused by Demodex folliculorum mites. Cytopathology. 2009 Mar 7. [Medline].

  4. Dhingra KK, Saroha V, Gupta P, Khurana N. Demodex-associated dermatologic conditions - A coincidence or an etiological correlate. Review with a report of a rare case of sebaceous adenoma. Pathol Res Pract. 2009 Jan 22. [Medline].

  5. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008 Apr. 43(2):170-9. [Medline].

  6. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008 Sep. 25(9):858-70. [Medline].

  7. Holzchuh FG, Hida RY, Moscovici BK, Villa Albers MB, Santo RM, Kara-José N, et al. Clinical Treatment of Ocular Demodex folliculorum by Systemic Ivermectin. Am J Ophthalmol. 2011 Jun. 151(6):1030-1034.e1. [Medline].

  8. Arky R. Acromycin V tetracycline HCl. Physicians' Desk Reference. 53rd ed. 1999. 1514-1515. [Full Text].

  9. Cohen EJ. Cornea and external disease in the new millennium. Arch Ophthalmol. 2000 Jul. 118(7):979-81. [Medline].

  10. Diaz-Valle D, Benitez del Castillo JM, Fernandez Acenero MJ. Bilateral lid margin ulcers as the initial manifestation of Crohn disease. Am J Ophthalmol. 2004 Aug. 138(2):292-4. [Medline].

  11. Fraunfelder FT, Roy FH, Steinemann TL. Current Ocular Therapy. 5th ed. 2000. 72, 374, 378, 450.

  12. Galea M, Sharma R, Srinivasan S, Roberts F. Demodex blepharitis mimicking eyelid sebaceous gland carcinoma. Clin Experiment Ophthalmol. 2013 Apr 9. [Medline].

  13. Held KS. Blepharitis. Decision Making in Ophthalmology. 2nd ed. 2000. 50-51.

  14. Kanski JJ. Marginal blepharitis. Clinical Ophthalmology. 1984. 1.2-1.4.

  15. Roy FH. Ocular Differential Diagnosis. 7th ed. 2002.

  16. Sullivan JH. Lids and lacrimal apparatus. General Ophthalmology. 14th ed. 1995. 78-81.

  17. Weisbecker CA, Fraunfelder FT, Rhee D. Physicians' Desk Reference for Ophthalmology. 28th ed. 2000.

  18. Yanoff M, Fine BS. Inflammation. Ocular Pathology. 4th ed. 1996. 166-168.

  19. Tighe S, Gao YY, Tseng SC. Terpinen-4-ol is the Most Active Ingredient of Tea Tree Oil to Kill Demodex Mites. Transl Vis Sci Technol. 2013 Nov. 2 (7):2. [Medline].

  20. Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000 Nov. 49 (11):619-26. [Medline].

  21. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev. 2006 Jan. 19 (1):50-62. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.